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Abstract
Family history of breast cancer is a key risk factor, accounting for up to 10% of cancers. We evaluated the proactive assess-
ment of familial breast cancer (FBC) risk in primary care. Eligible women (30 to 60 years) were recruited from eight English 
general practices. Practices were trained on FBC risk assessment. In four randomly-assigned practices, women were invited 
to complete a validated, postal family history questionnaire, which practice staff inputted into decision support software to 
determine cancer risk. Those with increased risk were offered specialist referral. Usual care was observed in the other four 
practices. In intervention practices, 1127/7012 women (16.1%) returned family history questionnaires, comprising 1105 
(98%) self-reported white ethnicity and 446 (39.6%) educated to University undergraduate or equivalent qualification, with 
119 (10.6%) identified at increased breast cancer risk and offered referral. Sixty-seven (56%) women recommended referral 
were less than 50 years old. From 66 women attending specialists, 26 (39.4%) were confirmed to have high risk and recom-
mended annual surveillance (40–60 years) and surgical prevention; while 30 (45.5%) were confirmed at moderate risk, with 
19 offered annual surveillance (40–50 years). The remaining 10 (15.2%) managed in primary care. None were recommended 
chemoprevention. In usual care practices, only ten women consulted with concerns about breast cancer family history. This 
study demonstrated proactive risk assessment in primary care enables accurate identification of women, including many 
younger women, at increased risk of breast cancer. To improve generalisability across the population, more active methods 
of engagement need to be explored.
Trial registration: CRUK Clinical Trials Database 11779.
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Introduction
Breast cancer is the commonest cancer in women in most 
countries [1], accounting for 30% of all cancers in women, 
with a lifetime risk of up to one in eight [2]. Women diag-
nosed at an early stage have a 5-year survival rate of 92% 
compared to 13% of women presenting at stage IV [3]. 
Mammographic screening for early cancer detection and 
appropriate intervention reduces breast cancer mortality 
and improves survival [4, 5]. However younger women, 
not routinely offered screening, may present symptomati-
cally with cancer at a later stage, with greater years of life 
thus lost [4–6]. This is associated with greater mortality in 
younger women diagnosed with breast cancer [7]. Further, 
these younger women are also more likely to have a genetic 
mutation and contralateral breast cancer [8, 9].
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Family history of breast cancer is a key risk factor, with 
the risk increasing according to the number of relatives [10] 
and first degree relatives affected, and diagnosis at a younger 
age [11]. Familial breast cancer accounts for up to 5–10% 
of diagnosed breast cancer cases, with the most common 
mutations occurring in the BRCA1/2 genes [12].
Taking a three-generation family history can identify 
women at increased familial risk for breast cancer [13–15]. 
English National Institute for Health and Care Excellence 
(NICE) guidelines recommend those identified at or near 
population risk (“average” risk) be followed up in primary 
care, with explanation of their level of risk and advice to 
update their family history regularly. Based on the nature of 
their family history, up to 1% of women are estimated to be 
at high familial risk (lifetime risk ≥ 30%), mainly with hered-
itary cancer syndromes. Another 2% are at moderate familial 
risk (17–30% lifetime risk), but do not have a specific cancer 
syndrome [16]. European Breast Cancer Specialist guide-
lines have defined high familial risk as greater than 20–30% 
lifetime risk [17]. More specifically, Dutch guidelines define 
moderate risk as 20–30% lifetime risk, whilst high risk is 
over 30% lifetime risk [18].
Identification of familial risk of breast cancer can lead 
to successful prevention strategies. Prophylactic bilateral 
mastectomy reduces breast cancer mortality and morbid-
ity in higher familial risk women, particularly those with 
BRCA1/2 genetic mutations [19, 20]. Further, yearly MRI 
and/or mammographic surveillance of women at moderate 
familial risk can reduce breast cancer mortality by up to 40% 
[21]. This improvement in health outcomes is also identi-
fied when offering surveillance to younger women [22, 23]. 
Chemoprevention can also reduce the risk of developing 
breast cancer [24, 25]. English NICE guidelines recommend 
women at high familial risk are offered chemoprevention, 
and chemoprevention be considered in those at moderate 
risk [14]. European guidelines do not give specific recom-
mendation on chemoprevention in usual clinical practice 
[17, 26–28]., Given the evidence for preventive surveillance 
and intervention, primary care may have a critical role in 
identifying women’s risk [29].
In UK primary care, standard usual (reactive) practice is 
to assess women opportunistically when they present with 
concerns about their family history [14]. There appears to 
be a similar reactive approach across Europe [30]. However 
this will fail to identify most women at increased cancer 
risk, particularly those from less advantaged communities 
and young women [6]. On the other hand, in busy primary 
care clinics, familial breast cancer risk assessment may be 
challenging for family physicians [31], resulting in a signifi-
cant number of unnecessary referrals to specialists and inap-
propriate mammographic imaging [26, 32–34]. Family His-
tory Risk Assessment Software (FaHRAS) has been helpful 
for decision support in hospital specialist settings [34]. For 
the current study, this has been modified, to incorporate 
information from a family history questionnaire previously 
validated with patients in primary care [35]. We sought to 
evaluate the proactive invitation of women for assessment 
of familial breast cancer risk, with use of decision support, 
in primary care.
Methods
This intervention study was performed between May 2014 
and September 2015. The study was approved by East Mid-
lands National Research Ethics Service (NRES) Committee 
(Reference 14/EM/0009). This involved recruiting family 
practices in central England. Initially, sixteen family prac-
tices expressed an interest in the study. After four practices 
were deemed outside of the catchment areas and another four 
declined after further information provided, eight practices 
were recruited to the study. In all eight practices, primary 
care teams (family physicians, office nurses and administra-
tive staff) received a one-hour education session on the iden-
tification of familial breast cancer, based on current national 
guidelines for England (NICE), including referral pathway 
for familial cancer risk assessment in hospital specialist 
care. In the recruitment area, the pathway involved general 
practitioners referring to the breast cancer service. Prior to 
the clinic appointment, the patient is sent a family history 
questionnaire by the service. This questionnaire is reviewed 
with the familial cancer nurse specialist, who will perform 
a breast cancer risk assessment. If women in moderate or 
high-risk categories are interested in chemoprevention, they 
are offered a further appointment with breast consultant to 
discuss pros and cons of treatment. Those women at very 
high risk are referred to regional clinical genetics service to 
consider genetic testing.
We randomly selected four practices who expressed an 
interest to adopt this proactive approach, using decision-sup-
port tool, and matched them by deprivation (nearest index 
of multiple deprivation decile [36] to four practices follow-
ing usual care. In the intervention practices, a familial risk 
assessment decision-support tool (primary care FaHRAS), 
using English NICE guidelines automated for risk stratifi-
cation and referral recommendation, was also presented to 
staff for use in practice [37]. All women, aged 30 to 60 years, 
were identified from practices’ electronic medical records. 
Women with a previously confirmed diagnosis of breast can-
cer or ovarian cancer, or who had had assessment for familial 
breast cancer risk in the preceding 12 months were excluded.
Women identified from this search were mailed an invita-
tion and a validated family history questionnaire (FHQ) [35] 
for completion. The FHQ was returned to their practice to 
enable primary care assessment of familial risk of breast 
cancer. No reminder invitation was sent. In addition, aligned 
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to national guideline recommendations and current “usual 
care”, eligible women who attended the practice with con-
cerns about their family history of breast cancer, over the 
next 8 months, were invited to complete the questionnaire 
[14]. Administrative staff in each practice were trained to 
enter women’s family history information into the familial 
risk assessment decision-support tool, which generated risk 
assessment and care advice for their family physician.
Based on current English (NICE) guidelines, there were 
three possible outcomes following assessment of women’s 
family history information by the decision support tool; 
average risk, increased risk or uncertain risk. Table 1 shows 
further details on familial risk stratification, based on NICE 
guidelines, and actions for patient following risk assessment.
The following measures were assessed: return of com-
pleted family history questionnaires (FHQ); accuracy of 
data entry from questionnaires to primary care FaHRAS 
tool achieved by primary care administrative staff (evalu-
ated by comparing this with that of research associate, 
trained by familial cancer nurse specialist, inputting the 
same family history information into the specialists version 
of the FaHRAS tool); numbers and proportions of women 
identified at “increased” risk and at “average” risk, before 
and after taking account of the “uncertain risk” category; 
and numbers and proportions of women confirmed to be 
classified at increased risk following specialist assessment 
and their subsequent management. Finally, at the end of the 
intervention period, recruited patients’ hospital and primary 
care records were reviewed to identify if recommended pre-
ventive surveillance or treatment was offered.
In the four other “usual care” practices, women consult-
ing their practice with concerns about breast cancer in their 
family history, over the same period were provided with care 
as usual.
Analysis was descriptive, with all outcome measures 
reported as numbers and percentages. Characteristics of 
the study population were presented as means and standard 
deviations for normally distributed continuous variables, 
medians and interquartile range for non-normally distrib-
uted continuous variables, and numbers and percentages for 
categorical variables. Descriptive analyses were conducted 
in STATA 15.
Results
In the four practices using a proactive approach and deci-
sion support, 1127 (16.1%) of 7012 eligible women returned 
completed family history questionnaires for assessment. A 
further 10 women who consulted in these four proactive 
practices, with family history concerns, also completed this 
questionnaire opportunistically. The sociodemographic pro-
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these women (55%) were aged under 50 years. Comparing 
recruited and non-recruited patients, they had a similar age 
distribution but ethnicity was better recorded in the recruited 
patients. Further details on recruited and non-recruited 
patients is given in Table S1.
Administrative staff at the practices correctly entered over 
99% (1134 of 1137) of patients’ family history data from 
these questionnaires. For three women, data were incorrectly 
inputted into software or information on the questionnaire 
was misinterpreted. In the four usual care practices, 10 
women consulted in the same period with concerns about 
family history of breast cancer.
Familial risk assessment outcomes
Risk assessment outcomes for the 1127 women proactively 
invited and assessed with decision support are shown in 
Fig. 1. In total, 999 (88.6%) patients were identified at-or 
near-population risk (average risk) and managed in primary 
care, and 128 women (11.4%) were assessed at increased 
risk with specialist referral recommended, of which 119 
offered referral for breast and related cancer risk.
Among the 999 women at average risk, 734 (65.1%) had 
no family history of breast, ovarian or prostate cancer, and 
265 (23.5%) had a family history of such cancers but were 
assessed as near population risk. 163 of the 265 women were 
identified by the decision software alone and the remaining 
102 women confirmed as near population risk after decision 
support software recommended discussion with a familial 
cancer specialist (“uncertain risk” category).
Among the 128 women at increased risk with specialist 
referral recommended, 64 (50%) women were confirmed by 
decision software alone, and the remaining 64 (50%) women 
initially assessed as ‘uncertain’ by decision software were 
then confirmed to be at increased risk after discussion with a 
specialist. Of these 128 women at increased risk, 71 women 
were under 50, and 68 had a family history of breast cancer 
only, 18 women had a family history of ovarian cancer only, 
32 women had a family history of both breast and ovarian 
cancer, and 1 woman had a family history of prostate can-
cer. In the remaining 9 women, there were 5 women who 
had familial colorectal cancer histories, one woman with a 
cancer syndrome family history, one woman with a sarcoma 
family history and two women were referred prior to receiv-
ing their risk assessment (see Table S2 for full details).
Outcomes of specialist referral
Outcomes of specialist referral are provided in Table 3. Of 
66 women referred during the intervention period, 56 were 
confirmed to be at increased risk by specialist assessment, 
26 (39.4%) were identified at high familial cancer risk of 
which 24 were offered yearly mammography. A further 30 
of these 56 women (45.5%) were classified by a specialist 
at moderately increased risk with 19 offered mammogra-
phy. In both high and moderately increased risk categories, 
confirmatory genetic testing was advised for 15 (26.8%) 
women’s living relatives (already diagnosed with cancer or 
with strong family history) rather than genetic testing of the 
recruited woman. Reviewing the primary and hospital elec-
tronic health records indicated none of the high or moderate 
Table 2  Demographics of Study Participants
a Other ethnicities include; White American, New Zealander, Russian, 
Brazilian, Filipino
b High School level is qualification at 16 (GCSEs), College level or 
equivalent qualification includes vocational, A Level or equivalent 
NVQ3 qualification, Higher education qualification is University 
Bachelor degree or equivalent qualification, No formal qualification 
indicates no qualification on leaving high school









 60 and above 63 5.6
Ethnicity
 White British or Irish 1105 98
 Black (inc. Caribbean, African) 5 0.4
 European of Jewish origin 5 0.4




 High school level 216 19.2
 College of equivalent 405 35.9
 Higher education 446 39.6
 No formal qualifications 48 4.3
 Missing 12 1.06
Deprivationc









 Least deprived 106 9.4
 Missing 61 5.3
Improving primary care identification of familial breast cancer risk using proactive invitation…
1 3
1 Referred as a duty of care due to family history of non-related breast/ovarian cancers 
2 At the time of data collection the participant had not been seen in specialist care, further details reported in text  
Eligible Participants 
N = 7012 
Average Risk 
N = 999 (88.64%)
Near Population Risk 
N = 265 (23.51%) 
Population Risk 
N = 734 (65.13%) 
FaHRAS Risk 
Assessment Outcome 
N = 1127 (16.1%) 
Increased Risk 
N = 128 (11.36%)
Referred before Assessment 
N = 2 (1.56%) 
Breast and Related 
N = 119 (92.97%) 
Other 
N = 7 (5.47%)1 
Further Specialist Assessment 
N = 66 (55.46%) 
No Specialist Assessment 
N = 53 (44.54%)2 
High Risk 
N = 26 (46.43%) 
Moderate Risk 
N = 30 (53.57%) 
Near Population Risk 
N = 10 (15.15%) 
Fig. 1  Risk Assessment Outcomes of Women Proactively Invited
Table 3  Outcome of referral to 
familial cancer specialist
a Denominator is based on total patients in moderate risk group
b Denominator is based on total patients in high risk group
Reason Number Proportion (%)
Near-population risk 10 15.2
Moderate increased risk 30 5.5
Yearly mammography offered 19 63.3a
   Exceeds age for increased surveillance (older than 50) 10 33.3a
   Below the age for increased surveillance (younger than 40) 6 20a
   Breast cancer identified; subsequent bilateral mastectomy 1 3.33a
Additional surveillance
   Patient referred for genetic mutation testing 0 0a
   Relative referred for genetic mutation testing 5 13.1a
   Genetic test result for relative received 0 0a
High increased risk 26 39.4
Yearly mammography offered 24 92.3b
   Exceeds age for increased surveillance (older than 50) 1 3.85b
   Below the age for increased surveillance (younger than 40) 1 3.85b
Additional surveillance
   Patient referred for genetic mutation testing 0 0b
   Relative referred for genetic mutation testing 10 38.5b
   Genetic test result for relative received 0 0b
Total 66
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risk women had been offered chemoprevention during the 
intervention period. The remaining 10 women were assessed 
by specialists at near-population risk and returned to be man-
aged in primary care.
At the time of data collection in hospital care, 53 of 119 
(43.7%) women identified in primary care at increased risk 
did not have further specialist assessment. This included 
16 women referred by their GP who did not attend special-
ist review (13) or who were referred to another secondary 
specialist (3); 11 women were not referred because they 
declined referral (6) or had previously been assessed by 
familial specialist or genetic services (5); and 21 women 
who did not respond to their GPs’ further invitations to dis-
cuss their results and referral. Finally, 5 women were lost to 
follow up and no information was available.
Women assessed opportunistically
Of the further 10 women assessed for familial breast cancer 
risk in the four “proactive” practices with breast cancer con-
cerns, 3 (all under 50 years old) were identified at increased 
familial breast cancer risk by decision support with referral 
recommended. In the other four “usual care” practices, none 
of the 10 women consulting had a documented family his-
tory risk assessment conducted as recommended by national 
(NICE) guidelines.
Discussion
This study has found proactive invitation and decision sup-
port in primary care enabled the accurate identification of 
women, including many younger women, at significantly 
increased risk of breast cancer. Following a single invita-
tion, 16% of eligible women provided their family history 
information and over 10% of them were newly identified, 
by decision support in primary care, at increased familial 
breast cancer risk with specialist referral recommended. The 
study also demonstrates primary care administrative staff 
can be trained to enter family history questionnaire, with 
over 99% of family history data correctly entered into the 
decision support software. The majority of women referred 
were confirmed at high or at moderate familial cancer risk by 
a familial cancer specialist, enabling the initiation of regular 
mammographic surveillance. One younger woman, aged 46, 
was thus diagnosed with early breast cancer within the study 
period itself.
Previous application of decision support in primary 
and secondary care have improved family history record-
ing and reduced unnecessary referrals [33, 34, 38]. In this 
study 2.7% of recruited women were classified at mod-
erate familial risk, whist 2.3% at high familial risk. The 
prevalence of moderate risk women was lower in a Dutch 
survey (1%) but higher in a Californian survey (6.7%) 
[39, 40]. The prevalence for women at higher familial risk 
was lower in this study compared to both the Dutch and 
Californian surveys. However, both surveys used differ-
ent definitions for familial risk classification. In the cur-
rent study, around a third of women at increased risk did 
not go for further specialist assessment when referred or 
when offered the opportunity. Continued primary care con-
tact with these women offers the opportunity to heighten 
awareness of risk and encourage follow up with specialist 
assessment, particularly if symptoms develop later. Pri-
mary care may be best placed to use decision support to 
inform appropriate future care of these women, includ-
ing encouraging follow up where active specialist assess-
ment or care is merited or for consideration of preventive 
treatment.
Women’s engagement following a single postal invitation 
was relatively modest but the intervention itself reached a 
large number of women in a short period of time using a pri-
mary care unsolicited postal survey with no reminders. This 
led to over 1100 women from four family practices return-
ing family history information, with over 10% identified at 
increased familial risk. Nevertheless, 84% of invited women 
did not return a questionnaire. Patients who responded and 
returned a questionnaire had a similar age distribution com-
pared to non-responders. If a similar 10% of non-responders 
also have an increased familial risk this would represent a 
large group of women and a significant unmet clinical need. 
While some selected response might be expected from those 
with a relevant family history, on-screen reminders and invi-
tations might increase uptake and identification of risk in 
practice [38]. This study further underlines the potential to 
readily use decision support when women do consult with 
concerns about family history or breast symptoms or have 
cancer family history collected in routine practice such as 
on registration with practice or starting oral contraception.
To our knowledge, this is the first study of proactive 
familial breast cancer risk assessment in women with 
unrecognised risk in UK primary care practice. The US 
Family Healthware Impact Trial [13], similarly to the cur-
rent study, recruited 18% of eligible patients by systematic 
identification using various recruitment modalities. Other 
similar primary care studies have primarily recruited women 
opportunistically when they have expressed concerns about 
this risk and then given a family history questionnaire to 
complete prior to their next booked consultation [33]. These 
approaches result in a higher recruitment rate, but we have 
shown in our current study that using only opportunistic 
approaches will lead to fewer women identified who would 
benefit from preventive interventions and/or surveillance. 
Like other studies that have used decision support tools in 
primary care with structured family history collection [38], 
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in this study, a high proportion of women were still classi-
fied at increased risk, following specialist assessment (85%).
Following specialist assessment, recommendations for 
surveillance, genetic testing and chemoprevention were 
aligned with English national (NICE) guidelines, recent 
studies and best practice in clinical genetics [14, 24, 25]. The 
reluctance to recommend chemoprevention has been con-
firmed by analysis of national primary care prescribing data 
[41]. The lack of prescribing may be explained by national 
guidelines only suggesting prescribing of chemoprevention 
to moderate risk women, whilst recommending chemopre-
vention in high risk women. In clinical practice the latter 
is usually only started after genetic mutation confirmed in 
affected relatives [14].
A significant proportion of women who responded and 
were confirmed to be at increased risk were from younger 
age groups. As the UK National Breast Screening pro-
gramme only starts at 50, these women would not have been 
detected by this screening programme. However, as men-
tioned earlier, there is strong evidence that surveillance of 
these younger women with increased familial risk improves 
disease outcomes [22, 23]. We recognise women from 
minority ethnic communities and those with low literacy 
are underrepresented among those women who engaged. We 
had anticipated a proactive and more systematic approach to 
identify familial risk, rather than awaiting consultation with 
family history concerns or symptoms, may be sufficient to 
reduce inequalities but this was not demonstrated [42]. More 
active direct strategies for engagement with these under-
served populations need to be developed [43].
This intervention study, with robust experimental 
design, was completed over a relatively short follow-up 
period, hence not all the referral outcomes could be veri-
fied or followed-up. Related to this, longer term outcomes 
related to genetic testing and cancer diagnoses could not be 
ascertained. Due to a small number of participants (n = 10) 
recruited through the four practices adopting usual oppor-
tunistic approach, comparison and statistically analysis 
between the participants in the proactive practices compared 
to usual care practices was not feasible. The opportunistic 
recruitment may be improved by patient-specific reminders 
in electronic health records [38]. Also, comparative data was 
not collected for specialist practitioners entering the same 
dataset but given the extremely high level of correct entry 
by the primary care administrative staff it is not envisaged 
that specialists would have entered data any more correctly.
This study suggests the considerable promise of proac-
tively engaging women to have familial cancer risk assess-
ment initiated by postal invitation. This is a relatively low 
cost strategy and can identify women at increased risk of 
breast cancer, who would otherwise not access the service, 
such as, younger women. Moreover, familial risk identifica-
tion is particularly relevant in women under 50 who are not 
routinely offered mammographic screening, and who cur-
rently present at a later stage of breast cancer (with more 
years of life to lose).
The study demonstrates that in women aged 30 to 
60 years, who respond and complete a validated family his-
tory questionnaire, up to 10% could be identified at increased 
breast cancer risk who may require specialist referral. This 
would require clear management pathways to manage finite 
specialist resources. Using current national guidelines, as 
many as 11% of women’s family histories were considered 
“uncertain risk” requiring primary care physician to discuss 
these with a specialist. This could be avoided if more refined 
primary care decision support were introduced. The use of 
such decision support software should be actively considered 
in order to support early detection with the role of better 
identifying those in need of referral and facilitating pathway 
improvements. Management pathways between primary care 
and specialists also needs to reinforce recommendation on 
chemoprevention for women at moderate and high familial 
risk of breast cancer.
Parallel qualitative study of women’s and primary care 
providers’ experiences of this approach is needed and will be 
reported separately. Further research might explore the use 
of decision support (compared to none) in primary care in 
a definitive clinical trial evaluating identification of women 
at increased familial breast cancer risk through systematic 
recruitment in both arms. Preceding the trial, there needs 
to be further intervention development to facilitate recruit-
ment of women from underserved populations [44]. Eco-
nomic evaluation would help identify cost and benefits of 
systematic assessment and prevention of cancer outcomes. 
A longer follow-up time frame would be required to ascer-
tain outcomes related to preventive treatment and clinical 
management of those at high risk. This includes genetic test 
results, chemoprevention, surgical prevention, and cancer 
diagnoses.
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